A gastrointestinal-focused biotechnology company developing therapies and discovery tools to restore and protect the gut mucosal-immune system. The company is advancing CS-0003, a first-in-class Mucosal-Immune Modulator, and GB, a metabolomics-based GI discovery platform, with an initial focus on preventing GI surgical site infections and potential expansion into IBD and prevention of colon cancer recurrence.
Leadership & Board
Current Number of Employees10
Current LinkedIn Followers1,007
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$40M
Total Amount Raised$40M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$40M
Latest Funding Amount$40M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
32 Biosciences had 10 employees as of September 14, 2026. The number of employees increased by 0 (0.00%) week-over-week.
10Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
32 Biosciences had 1,007 followers as of September 14, 2026. The number of followers increased by 3 (0.30%) week-over-week.
1,007Latest Followers Count
3(0.30%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.
Funding Round
Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Jan 08, 2026
Series A
$40.00M
―
Similar Companies
A snapshot of private companies similar to 32 Biosciences, helping you discover and navigate related company profiles.